Aphios Marine Therapeutics at BIT Marine Biotechnology World Congress
April 26, 2011

Woburn, MA — Aphios Corporation President and CEO Trevor P. Castor, Ph. D., today presented a lecture titled “Discovery and Development of Novel Therapeutics from Marine Organisms” at BIT’s 1st Annual World Congress of Marine Biotechnology-2011, held at Dalian World EXPO Center in Dalian, China. The theme of the conference was Ocean, Life and Sustainability.

The discovery and development of novel marine therapeutics for infectious diseases, cancer and other human diseases are being conducted through high throughput screening of marine organisms. To conduct this screening, we have developed a rapid sample preparation method that has been automated. This method utilizes SuperFluids™ or SFS (supercritical, critical or near-critical fluids with or without polar cosolvents such as an alcohol) for first, cell disruption, and second, polarity-guided fractional extraction of bioactive constituents.

Aphios Corporation has established a library of more than 1,400 unique marine microorganisms from diverse environments, including deep-sea sediments to shallow water mangrove swamps, tropical waters to temperate oceans, hydrothermal vents as well as normal saline to hyper-saline conditions. The microorganisms are fermented in four different marine media designed to maximize the diversity of secondary metabolites. Biodiversity is further enhanced by utilizing SFS to produce partially purified fractions of increasing polarity.

In a direct, large-scale and broad comparison with conventional organic phase (butanol) extraction by the Bristol-Myers Squibb Company, we have demonstrated that this process will increase the recovery and diversity of secondary metabolites, reduce interference from nuisance compounds and minimize background noise in sensitive enzymatic and molecular-based screens. Our pharmaceutical screening experiences have indicated a much higher proportion of bioactive “hits” in certain screens from these SFS fractions, at lower than normal metabolite concentrations. Aphios is utilizing this process of high throughput sample preparation and screening to develop novel anti-infective therapeutics for HIV, Influenza and Smallpox as well as Gingivitis and Multi-Drug Resistant (MDR) Bacteria.

Aphios Corporation® is a green biotechnology company developing enabling technology platforms for improved drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Based on these platforms, we are developing enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and Central Nervous System (CNS) disorders..

BIT Life Sciences, Inc. is a high-tech professional conference organizer service founded in Dalian, China. It is affiliated with more than 100 industrial associations and has relations with 100 top pharmaceutical manufacturers.